Condition (MeSH)
Porphyria Cutanea Tarda
ClinicalTrials.gov lists 6 trials for Porphyria Cutanea Tarda or a narrower condition beneath it. National Center for Research Resources (NCRR) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Porphyria Cutanea Tarda itself; the rest are tagged with a narrower condition beneath it.
When did Porphyria Cutanea Tarda trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2017 | 1 |
| 2011 | 1 |
| 2008 | 1 |
| 2006 | 1 |
| 2000 | 1 |
| 1999 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 6 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Porphyria Cutanea Tarda trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
| Observational | 2 |
How many Porphyria Cutanea Tarda trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 5 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Porphyria Cutanea Tarda trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Center for Research Resources (NCRR) | 1 |
Which serious adverse events do Porphyria Cutanea Tarda trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Coronary disease | 2 | 1 |
| Death | 1 | 1 |
| Prostate cancer | 1 | 1 |
Which publications cover Porphyria Cutanea Tarda? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C. | Digestive diseases and sciences | 2023 | Yes |
| Current applications of therapeutic phlebotomy. | Blood transfusion = Trasfusione del sangue | 2014 | Yes |
| Deferasirox for porphyria cutanea tarda: a pilot study. | Archives of dermatology | 2012 | Yes |
| Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2012 | Yes |
| Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2007 | No |
Showing 5 of 7 publications.
Prevalence (12)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Porphyria cutanea tarda | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Porphyria cutanea tarda | Annual incidence | 1-9 / 100 000 | Norway | Not stated | Exact |
| Porphyria cutanea tarda | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Porphyria cutanea tarda | Point prevalence | 1-5 / 10 000 | Sweden | Not stated | Unspecified |
| Porphyria cutanea tarda | Annual incidence | 1-9 / 100 000 | Norway | Not stated | Exact |
Showing 5 of 12 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Porphyria cutanea tarda | 101330 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Porphyria cutanea tarda | 101330 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.